Tag: relapsing multiple sclerosis

Novartis Presents New Four-Year Data on Efficacy and Safety of Kesimpta (ofatumumab) in People Living with Relapsing Multiple Sclerosis
April 5, 2022 Off

Novartis Presents New Four-Year Data on Efficacy and Safety of Kesimpta (ofatumumab) in People Living with Relapsing Multiple Sclerosis

By Author

Novartis has announced new long-term data from the Phase 3 ASCLEPIOS I/II trials and the ALITHIOS open-label extension that demonstrated long-term efficacy and safety of Kesimpta (ofatumumab), with continued reduced risk of disability worsening, for people living with relapsing multiple sclerosis following up to four years of treatment.